Unlisted Options Transactions, page-200

Fair call. Dr T can be seen as polarising based on comments here.

I personally disagree with the sentiment that he is ramping, but I have to be less single viewed and try and see it from a broader perspective.

The tricky thing is, a lot of Race's shareholders appreciate his honest input. I wonder if the less he communicates with his *current* shareholders, they become less involved with Race, and potentially less committed. Unfortunately, in life nothing is ever all pros. There will be negative and positives to any decision made. Potentially lose long term holders for new ones?

This is only in the scenario that Dr T's presence on forums has an impact on the market. If it doesn't, it really doesn't matter whether he is on or not.

At this stage, I'd say it doesn't matter in the short term. Race have their 30M to reach clinical results, and this will be what is more defining.